Bipolar disorder is a recurrent mood disorder characterized by episodes of mania (Bipolar I) or hypomania (Bipolar II) alternating with episodes of major depression. Bipolar disorder affects roughly 2.6% of Canadian adults lifetime (CCHS Mental Health Component) and is associated with significant morbidity, suicidality, and treatment complexity. Treatment-resistant bipolar depression (TRD in a bipolar context) is a particularly difficult clinical situation. This article is a safety-focused Canadian guide to when psychedelic-assisted therapy is and isn't appropriate for bipolar disorder: off-label ketamine has the strongest published bipolar-depression-specific evidence (Diazgranados 2010, Zarate 2012); Spravato is approved for TRD with explicit bipolar exclusion in the label; psilocybin and MDMA RCTs typically exclude bipolar patients due to mania-induction concerns. Mania-induction risk is the central safety consideration that distinguishes bipolar from unipolar mood disorder treatment. Mood stabilizer coordination is non-negotiable.

Key takeaways

Bipolar disorder affects ~2.6% of Canadian adults lifetime. Bipolar I (mania), Bipolar II (hypomania), cyclothymia.

Mania-induction risk is the central safety consideration that distinguishes bipolar from unipolar mood disorder treatment. Standard antidepressants can induce mania; psychedelic-assisted therapy carries similar concerns.

Off-label ketamine has the strongest published bipolar-depression-specific evidence: Diazgranados et al. 2010 and Zarate et al. 2012 showed rapid antidepressant response in bipolar depression with mood stabilizer coverage.

Spravato (esketamine) is Health Canada-approved for TRD with explicit bipolar exclusion in the label — Spravato should not be prescribed for bipolar depression unless very specific clinical conditions are met.

Psilocybin and MDMA RCTs typically exclude bipolar patients due to mania-induction concerns. Goodwin 2022 COMP001 excluded bipolar; Mitchell 2021/2023 MDMA-AT excluded bipolar.

Mood stabilizer coordination is non-negotiable before any consideration of off-label psychedelic-assisted therapy in bipolar populations.

Comprehensive psychiatric assessment is essential — bipolar misdiagnosis (often diagnosed as unipolar TRD) is a meaningful clinical risk if mood-history is not carefully assessed.

Suicidality risk in bipolar disorder is substantial — careful safety planning required.

Defining bipolar disorder

DSM-5 bipolar spectrum:

Bipolar I: at least one manic episode (≥1 week or hospitalization-required); often with major depressive episodes
Bipolar II: ≥1 hypomanic episode (≥4 days) AND ≥1 major depressive episode; no full mania
Cyclothymic disorder: ≥2 years of hypomanic and depressive symptoms not meeting full criteria
Mixed features: depressive episode with mania features or vice versa

Treatment-resistant bipolar depression is a particularly difficult clinical situation — often misdiagnosed initially as unipolar TRD when bipolar mood history was not carefully assessed.

Suicidality risk: bipolar disorder is associated with substantially elevated suicide risk — particularly during depressive and mixed episodes.

Mania-induction risk — the central safety consideration

Standard antidepressants (SSRIs, SNRIs, tricyclics) can induce mania or hypomania in bipolar patients without mood stabilizer coverage. This is the central safety consideration distinguishing bipolar from unipolar treatment.

For psychedelic-assisted therapy:

Ketamine and esketamine: glutamatergic mechanism distinct from monoamine antidepressants; mania risk appears lower but not zero
Psilocybin: serotonergic 5-HT2A agonist; mania-induction concerns based on serotonergic mechanism similarity to SSRIs
MDMA: serotonergic and dopaminergic mechanism; mania-induction concerns

This is why bipolar patients are typically excluded from psilocybin and MDMA RCTs — research safety concerns about mania induction in this population.

The bipolar evidence map for psychedelic-assisted therapy

Off-label ketamine for bipolar depression — strongest evidence

Diazgranados N, Ibrahim L, Brutsche NE, et al. 2010 (PMID 20530009): RCT of single-dose IV ketamine in bipolar depression; rapid antidepressant response with concurrent mood stabilizer (lithium or valproate).
Zarate CA Jr, Brutsche NE, Ibrahim L, et al. 2012 (PMID 22297150): replication RCT in bipolar depression; rapid antidepressant response with mood stabilizer.
Real-world Canadian KAP: ketamine has been used in carefully-screened bipolar depression patients with mood stabilizer coverage.
Mania risk in studied populations: low in studies with mood stabilizer coverage; not zero.

Spravato — bipolar exclusion in label

The Health Canada Spravato product monograph explicitly excludes bipolar disorder unless very specific clinical conditions are met. Off-label Spravato for bipolar depression is rarely the appropriate first choice given off-label generic ketamine has more direct bipolar evidence (Diazgranados/Zarate).

Psilocybin — exclusion in RCTs; case reports of caution

Goodwin 2022 COMP001 TRD trial: bipolar patients excluded
Carhart-Harris 2021 NEJM MDD trial: bipolar patients excluded
Real-world reports: case reports of mania induction in bipolar patients with psilocybin use exist; comprehensive screening for bipolar history is essential before any psilocybin SAP application
MAGNUS phase 3: continues to exclude bipolar disorder

MDMA — exclusion in RCTs

Mitchell 2021/2023 MAPP1/MAPP2 PTSD trials: bipolar patients excluded
Mithoefer 2018: bipolar patients excluded

For more detail see Ketamine for Bipolar Depression and the Ketamine Therapy in Canada guide.

Decision framework — bipolar-specific considerations

For bipolar patients considering psychedelic-assisted therapy:

Step	Question	Consequence
1	Is bipolar diagnosis confirmed by qualified psychiatrist?	If unclear/never assessed: comprehensive psychiatric assessment first
2	Is patient on mood stabilizer (lithium, valproate, lamotrigine, atypical antipsychotic)?	If no: mood stabilizer initiation/optimization first
3	Has bipolar depression failed standard treatments?	If first-line options remain: typically pursue first
4	Is patient currently in a manic / hypomanic / mixed episode?	If yes: psychedelic-assisted therapy contraindicated
5	Is suicidality acute?	If yes: comprehensive psychiatric care + safety planning first
6	What's the patient's response history to antidepressants — ever induced mania?	Past mania induction = much higher caution

Canadian access pathways

Comprehensive bipolar care first

Psychiatric care: bipolar disorder requires ongoing psychiatric specialist relationship — not just primary care or psychotherapy alone
Mood stabilizers: lithium, valproate, lamotrigine, quetiapine, lurasidone — provincial drug plans cover most options
Psychotherapy: CBT (cognitive behavioural therapy) for bipolar, IPSRT (interpersonal social rhythm therapy), family-focused therapy
Provincial mental health programs: most provinces have specialty bipolar/mood disorder clinics

Off-label ketamine for bipolar depression

Out-of-pocket dominantly: ~$400–$1,500/session
Mood stabilizer coverage required: not a candidate for off-label ketamine without mood stabilizer
Clinic capacity: most KAP clinics will accept carefully screened bipolar depression patients with established mood stabilizer regimen and psychiatric oversight

Psilocybin SAP for bipolar disorder

Generally not recommended for bipolar disorder given absence of RCT evidence and mania-induction concerns
Case-by-case Health Canada SAP applications would face significant clinical resistance
ATMA CENA will not typically support psilocybin SAP applications for bipolar primary indications

Spravato

Bipolar exclusion in label: Spravato should not be prescribed for bipolar depression unless very specific clinical conditions are met

What the evidence does NOT say

No psychedelic-assisted therapy is approved for bipolar depression in Canada.
Diazgranados/Zarate ketamine evidence does not generalize to all bipolar populations. Trial inclusion criteria typically required mood stabilizer coverage and stable bipolar disorder.
Mania-induction risk is real but quantification is uncertain. Larger surveillance data on psychedelic-induced mania would strengthen risk assessment.
Bipolar misdiagnosis is a meaningful clinical risk. Patients diagnosed with unipolar TRD who actually have bipolar depression may receive inappropriate psilocybin/MDMA referrals if mood-history is not carefully assessed.
Mixed features and rapid cycling — these subtypes are particularly high-risk for any antidepressant intervention.
Suicidality risk in bipolar disorder is substantial — careful safety planning required for any treatment intervention.

How ATMA CENA works with bipolar patients

ATMA CENA's bipolar-specific pathway:

Comprehensive intake: explicit bipolar mood history screening; family history; antidepressant response history
Psychiatric coordination: bipolar patients require ongoing psychiatric specialist relationship; ATMA CENA will not work with bipolar patients without confirmed mood stabilizer regimen and psychiatric oversight
Honest framing: ATMA CENA will route bipolar patients to standard-of-care first-line treatments before considering off-label ketamine adjunct
No psilocybin/MDMA for bipolar: ATMA CENA does not support psilocybin or MDMA SAP applications for bipolar primary indications given safety considerations

For more detail see Ketamine for Bipolar Depression.

Frequently asked questions

Can I do ketamine therapy if I have bipolar disorder? Possibly — but only with comprehensive psychiatric assessment, established mood stabilizer regimen, and psychiatric oversight. Diazgranados 2010 and Zarate 2012 RCTs showed rapid antidepressant response in bipolar depression with mood stabilizer coverage.

Can I do Spravato if I have bipolar disorder? The Spravato product monograph excludes bipolar disorder unless very specific clinical conditions are met. Off-label Spravato for bipolar depression is rarely the appropriate first choice.

Can I do psilocybin therapy if I have bipolar disorder? Generally no. Psilocybin RCTs (Goodwin 2022, Carhart-Harris 2021) exclude bipolar patients due to mania-induction concerns. Comprehensive screening for bipolar history is essential before any psilocybin SAP application.

Can I do MDMA-AT if I have bipolar disorder? Generally no. MDMA-AT RCTs (Mitchell 2021/2023, Mithoefer 2018) exclude bipolar patients due to mania-induction concerns.

What if I'm diagnosed with treatment-resistant depression but unsure about bipolar? This is a meaningful clinical risk. Bipolar misdiagnosis (often diagnosed as unipolar TRD when bipolar mood history was not carefully assessed) is common. Comprehensive psychiatric assessment with explicit mood-history screening is essential before any psychedelic-assisted therapy.

What about Bipolar II? Same general considerations. Mania-induction concerns extend to hypomanic episode induction.

What's the difference between unipolar TRD and bipolar depression treatment? Unipolar TRD treatments (SSRIs, SNRIs, ketamine, Spravato, psilocybin) can induce mania in bipolar patients. Bipolar depression treatment requires mood stabilizer coverage as foundational — and the evidence base for psychedelic-assisted therapy in bipolar is concentrated in ketamine with mood stabilizer (Diazgranados 2010, Zarate 2012).

What if I'm in a depressive episode now? Comprehensive psychiatric assessment first. Ketamine in bipolar depression with mood stabilizer coverage is supported by RCT evidence; psilocybin/MDMA generally contraindicated.

What if I have suicidality? Severe / suicidal bipolar depression requires comprehensive psychiatric care including safety planning. Hospital evaluation may be appropriate. Ketamine has demonstrated rapid suicidal ideation reduction but does not replace acute psychiatric care.

Can I share my bipolar diagnosis honestly with the clinical team? Yes — please do. Bipolar history is critical safety information; honest disclosure protects you. ATMA CENA's clinical team is non-judgmental and uses bipolar history to make appropriate clinical decisions, not to deny care reflexively.

Sources

Diazgranados N, Ibrahim L, Brutsche NE, et al. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 67(8):793-802. PMID: 20530009.
Zarate CA Jr, Brutsche NE, Ibrahim L, et al. (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry, 71(11):939-46. PMID: 22297150.
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Health Canada — Spravato Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
CANMAT and ISBD 2018 Guidelines for the Management of Patients with Bipolar Disorder: https://www.canmat.org/2019/02/05/2018-canmat-and-isbd-guidelines-for-the-management-of-patients-with-bipolar-disorder/
Statistics Canada — CCHS Mental Health Component (bipolar prevalence): https://www150.statcan.gc.ca/
Yatham LN, Kennedy SH, Parikh SV, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 20(2):97-170. PMID: 29536616.
Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry, 170(11):1249-62. PMID: 24030475.
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Public Health Agency of Canada — Mental Illness Surveillance: https://health-infobase.canada.ca/mental-illness/

Last updated: 2026-05-06

Bipolar Disorder and Psychedelic-Assisted Therapy — Safety Considerations